Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.

NCT04365374 is registered in ClinicalTrials.gov with GT Medical Technologies, Inc. as lead sponsor.

NCT NCT04365374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04365374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
Lead sponsor
GT Medical Technologies, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 6, 2021
Completion date
August 30, 2029
Enrollment
230 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases